Summary:
This is a phase 2 study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving donepezil HCl (10 mg qd) and either memantine HCl (10 mg twice daily [bid]) or Namenda XR® (28 mg qd) or the combination therapy, Namzaric™.
Qualified Participants Must:
• Qualified participants must be 50 to 85 years old and have Alzheimer's symptoms.
Qualified Participants May Receive:
Compensation for time and travel, participants may receive investigational medication or placebo.